Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era

Langenbeck's Archives of Surgery

Volumn 399, Issue 8, 2014, Pages 1021-1029

  Klose, Johannes ^a,b   Klose, Michelle A ^b   Metz, Courtney ^c   Lehner, Frank ^b   Manns, Michael P ^b   Klempnauer, Juergen ^b   Hoppe, Nils ^b,c   Schrem, Harald ^b   Kaltenborn, Alexander ^b,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d Department of Trauma and Orthopedic Surgery Federal Armed Forces Hospital   (Germany)

Author keywords

Autoimmune liver disease; Cholangiocarcinoma; MELD based allocation; Multivariate analysis; Outcome; Survival

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CHOLESTASIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GERMANY; GRAFT RECIPIENT; HEALTH CARE POLICY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LIVER TRANSPLANTATION; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT INDICATION; AGED; CHOLANGITIS, SCLEROSING; END STAGE LIVER DISEASE; EPIDEMIOLOGY; LENGTH OF STAY; MIDDLE AGED; OPERATION DURATION; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHOLANGITIS, SCLEROSING; END STAGE LIVER DISEASE; FEMALE; GERMANY; HEALTH POLICY; HUMANS; LENGTH OF STAY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OPERATIVE TIME; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; WAITING LISTS;

EID: 84911984544     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-014-1214-6     Document Type: Article

References (35)

1. Karlsen TH, Schrumpf E, Boberg KM (2010) Update on primary sclerosing cholangitis. Dig Liver Dis 42:390–400
2. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L (2004) Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 10:886–897
3. Brandsaeter B, Friman S, Broome U, Olausson M, Bäckman L, Hansen B et al (2003) Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 38:1176–1383
4. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneua TM et al (2003) Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125:1364–1369
5. Carbone M, Neuberger J (2011) Liver transplantation in PBC and PSC: indications and disease recurrence. Clin Res Hepatol Gastroenterol 35:446–454
6. Kim WR, Poterucha JJ, Wiesner RH, LaRusso NF, Lindor KD, Petz J et al (1999) The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 29:1643–1648
7. Freeman RB Jr, Gish RG, Harper A, Davis GL, Vierling J, Lieblein L et al (2006) Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 12(12 Suppl 3):S128–S136
8. German Medical Association (2008) Richtlinien zur Organtransplantation gem. § 16 TPG. Dtsch Arztebl 105:A1461–A1464
9. German Medical Association (2012) Richtlinien zur Organtransplantation gem. § 16 Abs. 1 S. 1 Nrn. 2 u. 5 TPG. Dtsch Arztebl 108:A662–A674
10. Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S et al (2011) Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany—limitations of the ‘sickest first’-concept. Transpl Int 24:91–99
11. Schlitt HJ, Loss M, Scherer MN, Becker T, Jauch KW, Nashan B et al (2011) Current developments in liver transplantation in Germany: MELD-based organ allocation and incentives for transplant centres. Z Gastroenterol 49:30–38
12. Eurotransplant Manual version 4.3; September 26, 2013; Chapter 5: 10–19
13. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
14. Schrem H, Kaltenborn A (2013) Germany: avoid more organ transplant scandals. Nature 498:37
15. Weismüller TJ, Negm A, Becker T, Barg-Hock H, Klempnauer J, Manns MP et al (2009) The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int 22:970–978
16. Kulkarni S, Cronin DC (2006) Ethics in liver transplantation. Semin Liver Dis 26(3):234–238
17. Schrem H, Reichert B, Frühauf N, Kleine M, Zachau L, Becker T et al (2012) Extended donor criteria defined by the German Medical Association: study on their usefulness as prognostic model for early outcome after liver transplantation. Chirurg 83:980–988
18. Brandsaeter B, Broome U, Isoniemi H, Friman S, Hansen B, Schrumpf E et al (2003) Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl 9:961–969
19. Maheshwari A, Yoo HY, Thuluvath PJ (2004) Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 99:538–542
20. Schrem H, Till N, Becker T, Bektas H, Manns MP, Strassburg CP et al (2008) Long-term results after liver transplantation. Chirurg 79:121–129
21. Goldberg D, French B, Thomasson A, Reddy KR, Halpern SD (2011) Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era. Liver Transpl 17:1355–1363
22. Cattan P, Berney T, Conti F, Conti F, Calmus Y, Homberg JC et al (2002) Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int 15:34–38
23. Schrem H, Reichert B, Fruhauf N, Becker T, Lehner F, Kleine M et al (2012) The Donor-Risk-Index, ECD-Score and D-MELD-Score all fail to predict short-term outcome after liver transplantation with acceptable sensitivity and specificity. Ann Transplant 17:5–13
24. Cameron AM, Ghobrial RM, Yersiz H, Farmer DG, Lipshutz GS, Gordon SA et al (2006) Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 243:748–753
25. Stahl JE, Tramontano AC, Swan JS, Cohen BJ (2008) Balancing urgency, age and quality of life in organ allocation decisions—what would you do? J Med Ethics 34:109–115
26. Feng S, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA et al (2006) Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 6:783–790
27. Reddy MS, Varguese J, Venkatamaran J, Rela M (2013) Matching donor to recipient in liver transplantation: relevance in clinical practice. World J Hepatol 5:603–611
28. Boberg KM, Lind GE (2011) Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol 25:753–764
29. Farges O, Malassagne B, Sebagh M, Bismuth H (1995) Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 117:146–155
30. Neuberger J, Gunson B, Komolmit P, Davies MH, Christensen E (1999) Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a Cox regression model. Hepatology 29:1375–1379
31. Wiesner RH (2001) Liver transplantation for primary sclerosing cholangitis: timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract Res Clin Gastroenterol 15:667–680
32. Fosby B, Karlsen TH, Melum E (2012) Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 18:1–15
33. Neil DA, Hübscher SG (2005) Current views on rejection pathology in liver transplantation. Transpl Int 23:971–983
34. Schrem H, Kurok M, Kaltenborn A, Vogel A, Walter U, Zachau L, Manns MP, Klempnauer J, Kleine M (2013) Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl 19:1252–1261
35. Reichert B, Kaltenborn A, Goldis A, Schrem H (2013) Prognostic limitations of the Eurotransplant-Donor Risk Index in liver transplantation. J Negat Results Biomed 12:18